Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jul 09, 2018 12:52pm
209 Views
Post# 28288290

RE:RE:RE:RE:RE:RE:Taimed sales

RE:RE:RE:RE:RE:RE:Taimed sales
palinc2000 wrote: I knew about the 6 mos but did not recall the in between testing,Thx for posting.Do you know if centralized  records  are kept for all patients  and who gets access to the compilation?


My understanding is CDC maintain databases, they are informed by the States and that data varies from State to State. Here is California resource page. Some of these document suggest around 15,000 in-treatment patient had viral failure in 2015 (of course most of those dont have MDR). My understanding is that number is around 120,000 nationally.

https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx

Given that we know Taimed need to do follow up post-approval work on resistance you might expect they are monitoring viral supression in Trogarzo patients but as you suggest there are privacy issues here in getting non-anonymous info. I'd be interested in knowing exactly what follow up taimed/thertech are doing with doctors/patients.


Bullboard Posts